Novartis AMD drug Beovu secures European approval
European drug regulators have followed in the footsteps of their Australian and US counterparts, following the approval of Novartis’ new ...
Tag: AMD
Patient receives first wireless retinal device implant
A surgeon at the University of Pittsburgh Medical Center (UPMC) has implanted the first patient in the US with a ...
Study highlights biomarker for discontinuing anti-VEGF treatment
A new study has demonstrated that a particular biomarker can be used to select which age-related macular degeneration (AMD) patients ...
New type of tissue found in the eye
Researchers have found cellular components in the epithelial tissue of the eye that were previously only thought to be present ...
Major Melbourne study a world-first for AMD
An Australian-led study has received $5 million to undertake the world’s most intensive investigation into why a particular group of ...
Novartis targets Europe for next-generation AMD treatment
Novartis’ new therapy for neovascular age-related macular degeneration (nAMD) has advanced part-way through the European regulatory process after winning the ...
Warmth may improve effectiveness of anti-VEGF injections
Inconsistent or ineffective age-related macular degeneration (AMD) treatments might be solved by an easy solution, according to new research from ...
Biogen unveils plan to commercialise Eylea and Lucentis generics
Multinational biotech company Biogen has proposed a deal worth up to US$310 million (AU$453 m) to supply biosimilar treatments of ...
Melbourne study to put new AMD tools under microscope
The University of Melbourne is recruiting optometrists to test new clinical tools, as well as an auditing system, it has ...
FDA clears Novartis’ new treatment for nAMD
Novartis has secured US regulatory approval for Beovu, the company’s latest therapy for neovascular age-related macular degeneration (nAMD), following the ...